Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7618MR)

This product GTTS-WQ7618MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7618MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1580MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ13933MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ7499MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ15739MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ15115MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ13433MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ3449MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ12659MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-18R5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW